Chronic atrophic gastritis with intestinal metaplasia
Conditions
Interventions
Joint Group:Combined moxibustion on the basis of the treatment group 1 time / d each time 30 min
Treatment Group:Treated with Spleen and Stomach Peiyuan Formula, 2 times/d, 1 h after meal
Control group:Rebapatide tablets combined with folic acid tablets both 1 tablet/dose 3 times/d 1 h before meal.
Sponsors
Department of Spleen and Stomach The Second Affiliated Hospital of Anhui University of Traditional Chinese Medicine China
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1) Those who meet the diagnostic criteria by endoscopy and pathological tissue biopsy; (2) Those who have stable vital signs after conventional treatment and the duration of the disease is less than 3 months; (3) Those with clinical manifestations of the digestive tract such as abdominal distension abdominal pain gastric discomfort belching and acid reflux; (4) Those who voluntarily participate in this clinical trial give informed consent and sign the informed consent form; (5) Aged 18 to 75 years old gender is not limited; (6) Those with complete clinical data.
Exclusion criteria
Exclusion criteria: (1) Patients who have taken proton pump inhibitors (PPIs) and other drugs that may affect the function of the digestive tract within the last 2 weeks; (2) Patients who have taken antibiotics in the last 1 month; (3) Those who have a combination of serious digestive tract haematological neurological malignancies and other primary diseases; (4) Patients with conscious disorders; (5) Those with cognitive dysfunction; (6) Those with severe multi-organ failure; (7) Patients with a history of alcohol consumption within 2 weeks; (8) Patients with Helicobacter pylori infection; (9) Patients with allergy to the drug components in this study; (10) Those with imperfect clinical data; (11) Patients who are also participating in other clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| OLGA staging;clinical symptom score;OLGIM staging;Endoscopic gastric mucosal pathological tissue score;PRO scale; | — |
Secondary
| Measure | Time frame |
|---|---|
| incidence of adverse reactions;; | — |
Countries
China
Contacts
Public ContactXuejun Li
The Second Affiliated Hospital of Anhui University of Traditional Chinese Medicine
Outcome results
None listed